International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis

Gut, Journal Year: 2019, Volume and Issue: 68(9), P. 1624 - 1632

Published: May 15, 2019

In this consensus statement, an international panel of experts deliver their opinions on key questions regarding the contribution human microbiome to carcinogenesis.International in oncology and/or research were approached by personal communication form a panel. A structured, iterative, methodology based around 1-day roundtable discussion was employed derive expert microbiome-oncology research.Some 18 convened for and five identified regarding: (1) relevance dysbiosis/an altered gut carcinogenesis; (2) potential mechanisms microbiota-induced (3) conceptual frameworks describing how may drive (4) causation versus association; (5) future directions field.The considered that, despite mechanistic supporting evidence from animal studies, there is currently no direct that commensal determinant aetiopathogenesis cancer. The cited lack large longitudinal, cohort studies as principal deciding factor agreed should be priority. However, while acknowledging gaps evidence, opinion microbiome, alongside environmental factors epigenetically/genetically vulnerable host, represents one apex tripartite, multidirectional interactome drives carcinogenesis.Data longitudinal are needed confirm role driver

Language: Английский

---

The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer

Cell Metabolism, Journal Year: 2022, Volume and Issue: 34(4), P. 581 - 594.e8

Published: March 11, 2022

Language: Английский

---

Gut Microbiota in Cancer Immune Response and Immunotherapy

Trends in cancer, Journal Year: 2021, Volume and Issue: 7(7), P. 647 - 660

Published: March 2, 2021

Language: Английский

---

Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy

Cancer Discovery, Journal Year: 2020, Volume and Issue: 10(12), P. 1797 - 1807

Published: Nov. 3, 2020

Cancer cells continuously rewire their metabolism to fulfill need for rapid growth and survival while subject changes in environmental cues. Thus, a vital component of cancer cell lies its metabolic adaptability. The constant demand alterations requires flexibility, that is, the ability utilize different substrates; as well plasticity, process substrates ways. In this review, we discuss how dynamic affect tumor progression consequential implications therapy. SIGNIFICANCE: Recognizing adaptability an entity can lead targeted therapy is expected decrease drug resistance.

Language: Английский

---

Nanotechnology intervention of the microbiome for cancer therapy

Nature Nanotechnology, Journal Year: 2019, Volume and Issue: 14(12), P. 1093 - 1103

Published: Dec. 1, 2019

Language: Английский

---

Tumor Microenvironment‐Enabled Nanotherapy

Advanced Healthcare Materials, Journal Year: 2017, Volume and Issue: 7(8)

Published: Dec. 28, 2017

Cancer is now one of the world's leading threats to human health. With development oncology in both biology and biomedicine, it has been demonstrated that abnormal physiochemical conditions dysregulated biosynthetic intermediates tumor microenvironment (TME) play a pivotal role enabling cells defend or evade damage by traditional clinical therapeutics including surgery, chemotherapy, radiotherapy, etc. The fast advances TME-enabled theranostic nanomedicine have offered promising perspectives, strategies, approaches for combating cancer based on novel concept nanotherapy. In this comprehensive review, origins TME (e.g., enhanced permeability retention effect, overexpressed intermediates, mild acidic nature, redox potentials, hypoxia) are initially introduced discussed, followed detailed discussion overview state-of-the-art progresses antitumor nanotherapies chemo/chemodynamic therapy, photodynamic radiotherapy). Finally, obstacles challenges future further translation outlooked.

Language: Английский

---

Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers

Journal for ImmunoTherapy of Cancer, Journal Year: 2021, Volume and Issue: 9(12), P. e003334 - e003334

Published: Dec. 1, 2021

The gut microbiome is associated with the response to immunotherapy for different cancers. However, impact of on hepatobiliary cancers receiving remains unknown. This study aims investigate relationship between and clinical anti-programmed cell death protein 1 (PD-1) in patients advanced cancers.Patients unresectable hepatocellular carcinoma or biliary tract who have progressed from first-line chemotherapy (gemcitabine plus cisplatin) were enrolled. Fresh stool samples collected before during anti-PD-1 treatment analyzed metagenomic sequencing. Significantly differentially enriched taxa prognosis identified. Kyoto Encyclopedia Genes Genomes database MetaCyc further applied annotate explore potential mechanism influencing cancer immunotherapy.In total, 65 included this study. Seventy-four significantly benefit (CBR) group 40 non-clinical (NCB) group. Among these taxa, higher abundance Lachnospiraceae bacterium-GAM79 Alistipes sp Marseille-P5997, which CBR group, achieved longer progression-free survival (PFS) overall (OS) than lower abundance. Higher Ruminococcus calidus Erysipelotichaceae bacterium-GAM147 was also observed better PFS. In contrast, worse PFS OS found Veillonellaceae, NCB Functional annotation indicated that energy metabolism while amino acid metabolism, may modulate addition, immunotherapy-related adverse events affected by diversity relative abundance.We demonstrate Taxonomic signatures responders are effective biomarkers predict immunotherapy, might provide a new therapeutic target immunotherapy.

Language: Английский

---

Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events

Frontiers in Medicine, Journal Year: 2019, Volume and Issue: 6

Published: May 29, 2019

In the last decade, inhibitors targeting immune checkpoint molecules such as cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and death-ligand (PD-L1) brought about a major paradigm shift in cancer treatment.These (ICIs) improved overall survival of variety malignant melanoma non-small lung cancer.In addition, numerous clinical trials for additional indication ICIs including adjuvant neo-adjuvant therapies are also currently ongoing.Therefore, more patients will receive future.However, despite outcome treatment by ICIs, efficacy remains still limited tumor regression have not been obtained many patients.In with is associated substantial toxicities, described immune-related adverse events (irAEs).Therefore, biomarkers to predict response occurrence irAEs required avoid overtreatment minimize development.Whereas, factors reported potential predicting irAE less reported.In this review, we show recent advances understanding treated ICIs.

Language: Английский

---

The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?

Frontiers in Immunology, Journal Year: 2020, Volume and Issue: 11

Published: Oct. 8, 2020

Immune checkpoint inhibitors (ICIs) are a novel class of immunotherapy drugs that have improved the treatment broad spectrum cancers as metastatic melanoma, non-small lung cancer or renal cell carcinoma. These humanized monoclonal antibodies target inhibitory receptors (e.g. CTLA-4, PD-1, LAG-3, TIM-3) and ligands (PD-L1) expressed on T lymphocytes, antigen presenting cells tumor elicit an anti-tumor response by stimulating immune system. Nevertheless, overall survival is complicated manifestation Immune-related Adverse Effects (irAEs). During with ICIs, most common adverse kidney effect represented development acute injury (AKI) tubulointerstitial nephritis recurrent histological feature. The mechanisms involved in ICIs-induced AKI include re-activation effector previously stimulated nephrotoxic (i.e. antibiotics), loss tolerance versus self-renal antigens, increased PD-L1 expression tubular establishment pro-inflammatory milieu release self-reactive antibodies. For transplant recipient treated incidence rejection serious concern. Therefore, combination ICIs mTOR represents emerging strategy. Finally, it relevant to anticipate which patients under would experience severe irAEs from perspective, predict higher risk AKI. Here, we provide detailed overview ICIs-related nephrotoxicity recently described multicenter studies. Several factors been reported biomarkers ICIs-irAEs, this review speculate potential for ICIs-associated

Language: Английский

---

Gut Microbiota Shapes the Efficiency of Cancer Therapy

Frontiers in Microbiology, Journal Year: 2019, Volume and Issue: 10

Published: June 25, 2019

Summary: The homeostasis of gut microbiome is linked with the balance host immune system. Increasing evidence showed that cancer therapy would perturb response and result dysbiosis system, which influenced efficiency therapy. microbes play increasingly significant role in deepening research, modulate drug efficacy, abolish anti-cancer effect, mediate toxicity. systems biology provides an opportunity to discover important microbiota playing almost all aspects human health. existed provokes a hypothesis closely related pharmacological effects chemical novel targeted immunotherapy. Gut shapes drugs through several key mechanisms (metabolism, immunomodulation, translocation, enzymatic degradation, reduction diversity ecological variability). Therefore, emerges as target enhance efficacy reduce toxicity adverse effect In this review, we outlined modulating implication improving chemotherapy immunotherapy clinical practice. We also summarized current situation limitations safety effectiveness probiotics personalized

Language: Английский

---